Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review
ObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who recei...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8f697cc520de4b24ac690fc280760438 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8f697cc520de4b24ac690fc280760438 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8f697cc520de4b24ac690fc2807604382021-11-17T05:14:43ZStevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review2234-943X10.3389/fonc.2021.736975https://doaj.org/article/8f697cc520de4b24ac690fc2807604382021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.736975/fullhttps://doaj.org/toc/2234-943XObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.ResultsSJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.ConclusionMost cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment.Min DengMin DengHuirong ChaiMeng YangXueman WeiWenjun ZhangXuebin WangJuanjuan LiZhuo WangZhuo WangHaitao ChenFrontiers Media S.A.articleenzalutamideStevens-Johnson syndromedrug eruptioncutaneous adverse eventsprostate cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
enzalutamide Stevens-Johnson syndrome drug eruption cutaneous adverse events prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
enzalutamide Stevens-Johnson syndrome drug eruption cutaneous adverse events prostate cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| description |
ObjectiveEnzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.MethodsWe present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.ResultsSJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.ConclusionMost cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment. |
| format |
article |
| author |
Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen |
| author_facet |
Min Deng Min Deng Huirong Chai Meng Yang Xueman Wei Wenjun Zhang Xuebin Wang Juanjuan Li Zhuo Wang Zhuo Wang Haitao Chen |
| author_sort |
Min Deng |
| title |
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_short |
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_full |
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_fullStr |
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_full_unstemmed |
Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review |
| title_sort |
stevens-johnson syndrome caused by enzalutamide: a case report and literature review |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/8f697cc520de4b24ac690fc280760438 |
| work_keys_str_mv |
AT mindeng stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT mindeng stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT huirongchai stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT mengyang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT xuemanwei stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT wenjunzhang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT xuebinwang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT juanjuanli stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT zhuowang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT zhuowang stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview AT haitaochen stevensjohnsonsyndromecausedbyenzalutamideacasereportandliteraturereview |
| _version_ |
1718425939645300736 |